Aurinia Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Aurinia Pharmaceuticals

01/08/2023 19:37

* Aurinia Pharmaceuticals Inc  AUPH.OQ   AUPH.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 3. 
    * The Victoria British Columbia-based  company is expected
to
report  a 35.3% increase in revenue to $38.147 million from
$28.19 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aurinia
Pharmaceuticals
Inc is for a loss of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $15​, above​ its last closing price
of $11.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.22       -0.22      -0.18     Beat    18.7
 Dec. 31 2023  -0.27       -0.27      -0.18     Beat    34
 Sep. 30 2022  -0.17       -0.17      -0.06     Beat    64.4​
 Jun. 30 2022  -0.22       -0.22      -0.25     Missed  -11.9
 ​​Mar.        -0.27       -0.27      -0.27     Met     -1.1
 31 2022                                                
 Dec. 31 2021  -0.27       -0.27      -0.25     Beat    6.9​
 Sep. 30 2021  -0.34       -0.33      -0.39     Missed  -17.2
 Jun. 30 2021  -0.37       -0.36      -0.37     Missed  -1.6
 This summary was machine generated August 1 at 18:36 GMT.  All
figures in US dollars  unless otherwise stated